Ebixa® in Alzheimer’s disease

Ebixa^® has been studied in six main studies, and has proven to be more effective than placebo (a dummy treatment) at controlling the symptoms of Alzheimer's disease. The Ebixa treatment results in stabilisation or less pronounced deterioration in key domains

• Functional (the degree of disability)
• Cognitive (ability to think, learn and remember)
• Behaviour
• Global

The overall frequency of patients who experienced side-effects was similar with Ebixa^® compared to placebo.

Please refer to your local prescribing information for more specific details about Ebixa^® in your country. If you are a patient or carer and have further questions on Ebixa^®, please ask your physician or pharmacist. As health-care professional, please refer to the specific section of this website.

How it works
Nerve cells in the brain – neurons – communicate with each other via electric signals, but also by using messenger substances, called “neurotransmitters”. One of these substances is glutamate. Glutamate is the most frequently used neurotransmitter in the central nervous system, accounting for approximately 70% of all of its excitatory neurotransmission.

Glutamate is believed to be closely linked to the memory and learning process, by regulating the uptake and level of calcium in the neurons. In AD, glutamate release and uptake are chronically dysfunctional, causing an elevated flow of calcium into the neurons.

Ebixa^® is an uncompetitive, moderate affinity, NMDA (N-methyl-D-aspartate) receptor antagonist that binds to the NMDA receptor channel, and regulates the calcium influx into the neurons.

Healthcare professionals

Ebixa^® is licensed for the treatment of moderate to severe Alzheimer’s disease. As a healthcare professional, we invite you to explore the following website for further information; www.ebixa.com.